Document type
ArticleVersion
Published versionPublication date
Publication license
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/202134
Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
The advent of immunotherapy has revolutionized cancer treatment. Unfortunately, this has not been the case for metastatic castration-resistant prostate cancer (mCRPC), likely due to the heterogeneous and immune-suppressive microenvironment present in prostate cancer. The identification of molecular biomarkers that could predict response to immunotherapy represents one of the current challenges in this clinical scenario. The management of advanced castrationresistant prostate cancer is rapidly evolving and immunotherapy treatments, mostly consisting of immune checkpoint inhibitors combinations, BiTE (R) (bispecific T-cell engager) immune therapies, and chimeric antigen receptors (CAR) are in development with promising results. This review analyses the current evidence of immunotherapy treatments for mCRPC, evaluating past failures and promising approaches and discussing the directions for future research.
Subject
Subject (English)
Citation
Citation
LÓPEZ CAMPOS, Fernando, et al. Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions. Biomedicines. 2022. Vol. 10, num. 3. ISSN 2227-9059. [consulted: 14 of August of 2026]. Available at: https://hdl.handle.net/2445/202134